Showing 828 results
-
Media Release /- As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease(1)- In the Phase III trial, most patients…
-
Media Release /- Phase III study published in NEJM today and to be presented tomorrow met primary endpoint in moderate-to-severe chronic idiopathic urticaria (CIU)- CIU can be a serious, debilitating form of hives…
-
Media Release /- Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation- Approval based on…
-
Media Release /-- Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate1-- Patients with NTDT accumulate…
-
Media Release /- Discounts and rebates by pharmaceutical companies are a customary, appropriate and legal practice as recognized by the Government- Physician speaker programs are also an accepted practice designed…
-
Media Release /- TOBI Podhaler is portable and requires no nebulizer, refrigeration or power source to deliver the medicine- TOBI Podhaler is indicated for certain cystic fibrosis (CF) patients with Pa and shortens…
-
Media Release /-- Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS1-- Gilenya is the first oral…
-
Media Release /-- "Together in MS" tandem teams have pedaled 1,000 miles in 15 National MS Society "Bike MS" events since 2011-- Campaign pairs pro women's cyclists and people with MS to raise awareness of multiple…
-
Media Release /-- At six months, adjusted mean treatment satisfaction scores increased by a statistically significant 20.4 with Gilenya vs. 2.9 with injectable disease modifying therapies1-- In one of the largest…
-
Media Release /- Latest Phase III research on Afinitor® in advanced HER2 positive breast cancer- Jakavi™ overall survival advantage evaluated in three-year study in patients with myelofibrosis, a rare and life-…
